Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 08 2020
Historique:
entrez: 19 8 2020
pubmed: 19 8 2020
medline: 29 12 2020
Statut: epublish

Résumé

Despite studies showing that repeated cannabis use may worsen depressive symptoms, the popular media increasingly presents cannabis as beneficial to mental health, and many members of the public view cannabis as beneficial for depression. Therefore, cannabis use among individuals with depression may be becoming more prevalent. To examine the association of depression with past-month cannabis use among US adults and the time trends for this association from 2005 to 2016. This repeated cross-sectional study used data from 16 216 adults aged 20 to 59 years who were surveyed by the National Health and Nutrition Examination Survey, a national, annual, cross-sectional survey in the United States, between 2005 and 2016. Data analysis was conducted from January to February 2020. Survey year and depression, as indicated by a score of at least 10 on the Patient Health Questionnaire-9. Any past-month cannabis use (ie, ≥1 use in the past 30 days) and daily or near-daily past-month cannabis use (ie, ≥20 uses in the past 30 days). Logistic regression was used to examine time trends in the prevalence of cannabis use, depression, and the association between cannabis use and depression from 2005 to 2016. The final analysis included 16 216 adults, of whom 7768 (weighted percentage, 48.9%) were men, 6809 (weighted percentage, 66.4%) were non-Hispanic White participants, and 9494 (weighted percentage, 65.6%) had at least some college education. They had a weighted mean age of 39.12 (95% CI, 38.23-39.40) years. Individuals with depression had 1.90 (95% CI, 1.62-2.24) times the odds of any past-month cannabis use and 2.29 (95% CI, 1.80-2.92) times the odds of daily or near-daily cannabis use compared with those without depression. The association between cannabis use and depression increased significantly from 2005 to 2016. The odds ratio for depression and any past-month cannabis use increased from 1.46 (95% CI, 1.07-1.99) in 2005 to 2006 to 2.30 (95% CI, 1.82-2.91) in 2015 to 2016. The odds ratio for depression and daily or near-daily past-month cannabis use increased from 1.37 (95% CI, 0.81-2.32) in 2005 to 2006 to 3.16 (95% CI, 2.23-4.48) in 2015 to 2016. The findings of this study indicate that individuals with depression are at increasing risk of cannabis use, with a particularly strong increase in daily or near-daily cannabis use. Clinicians should be aware of these trends and the evidence that cannabis does not treat depression effectively when discussing cannabis use with patients.

Identifiants

pubmed: 32809032
pii: 2769386
doi: 10.1001/jamanetworkopen.2020.13802
pmc: PMC7435337
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2013802

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA048860
Pays : United States

Références

Drug Alcohol Depend. 2011 Jul 1;116(1-3):93-101
pubmed: 21277712
Lancet Psychiatry. 2016 Oct;3(10):954-964
pubmed: 27592339
Vital Health Stat 2. 2014 Mar;(162):1-33
pubmed: 25569458
J Affect Disord. 2013 Jun;148(2-3):188-95
pubmed: 23260381
CMAJ Open. 2018 Aug 16;6(3):E339-E346
pubmed: 30115639
Psychol Med. 2006 Oct;36(10):1447-60
pubmed: 16854249
Prev Sci. 2017 Feb;18(2):183-192
pubmed: 27534665
J Affect Disord. 2017 Apr 15;213:168-171
pubmed: 28242498
Prev Sci. 2019 Feb;20(2):215-223
pubmed: 29767282
J Psychiatr Res. 2019 Apr;111:134-139
pubmed: 30738930
J Gen Intern Med. 2020 Jan;35(1):153-159
pubmed: 31637640
Vital Health Stat 2. 2013 Aug;(160):1-23
pubmed: 25090039
Soc Sci Med. 2019 Jul;233:181-192
pubmed: 31207470
J Subst Abuse Treat. 2017 Oct;81:53-58
pubmed: 28847455
Curr Drug Abuse Rev. 2008 Jan;1(1):81-98
pubmed: 19630708
Mayo Clin Proc. 2013 Jan;88(1):56-67
pubmed: 23274019
Can J Psychiatry. 2015 Jan;60(1):23-30
pubmed: 25886546
Vital Health Stat 1. 2013 Aug;(56):1-37
pubmed: 25078429
Drug Alcohol Depend. 2018 May 1;186:10-15
pubmed: 29525698
J Affect Disord. 2016 May;195:63-74
pubmed: 26872332
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Neuropsychopharmacology. 2018 Jan;43(1):195-212
pubmed: 28853439
Cannabis Cannabinoid Res. 2016 Dec 01;1(1):244-251
pubmed: 28861496
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:285-308
pubmed: 27618739
NCHS Data Brief. 2018 Feb;(303):1-8
pubmed: 29638213
Addiction. 2020 May;115(5):935-943
pubmed: 31797462
MMWR Surveill Summ. 2016 Sep 02;65(11):1-28
pubmed: 27584586
Drug Alcohol Rev. 2016 May;35(3):326-33
pubmed: 26364922
Am J Med. 2017 Jun;130(6):678-687.e7
pubmed: 28161344
Ann Intern Med. 2018 Sep 4;169(5):282-290
pubmed: 30039154
Drug Alcohol Depend. 2015 Apr 1;149:232-44
pubmed: 25735467
J Psychoactive Drugs. 2011 Apr-Jun;43(2):128-35
pubmed: 21858958
Clin Toxicol (Phila). 2015 Mar;53(3):151-5
pubmed: 25646638
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
J Pain Res. 2017 May 02;10:989-998
pubmed: 28496355
J Gen Intern Med. 2018 Sep;33(9):1438-1440
pubmed: 29845473
J Health Commun. 2018;23(12):1036-1043
pubmed: 30395785
Lancet. 2009 Oct 17;374(9698):1383-91
pubmed: 19837255
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
Curr Pharm Des. 2014;20(13):2138-67
pubmed: 23829361
JAMA Psychiatry. 2015 Dec;72(12):1235-42
pubmed: 26502112
Vital Health Stat 2. 2012 May;(155):1-39
pubmed: 22788053

Auteurs

Lauren R Gorfinkel (LR)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
New York State Psychiatric Institute, New York.

Malki Stohl (M)

New York State Psychiatric Institute, New York.

Deborah Hasin (D)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
New York State Psychiatric Institute, New York.
Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH